Literature DB >> 19967456

Female BRCA mutation carriers with a preference for prophylactic mastectomy are more likely to participate an educational-support group and to proceed with the preferred intervention within 2 years.

Karin M Landsbergen1, Judith B Prins, Yvonne J L Kamm, Han G Brunner, Nicoline Hoogerbrugge.   

Abstract

Women with a BRCA mutation face a complex choice between breast cancer surveillance and prophylactic mastectomy. We determined risk management preferences shortly after genetic test disclosure and mastectomy status after a median observation period of 2 years. The effect of an educational-support group on the realisation of risk management preference was explored. We included 163 newly disclosed BRCA mutation carriers with no history of cancer, whose breast cancer risk management preferences were recorded. All carriers were offered the opportunity to participate an educational-support group. Mastectomy status was checked after a median observation period of 2 years. Of the total sample, 27% had an initial preference for mastectomy and 48% attended an educational-support group. After a median observation period of 2 years, 30% of the total sample had undergone prophylactic mastectomy. Of the women with a preference for surveillance, 90% of educational-support group attendees and 88% of the other mutation carriers, were still under surveillance. The number of women with a preference for mastectomy who actually had a mastectomy performed, was significantly higher in the group that attended an educational-support group as compared to those who did not, 89% and 63% respectively (OR 4.8, P = 0.04). Strong predictors for prophylactic mastectomy within 2 years were younger age and prior preference for mastectomy (R (2) = 0.57). Nearly all BRCA mutation carriers proceed with their initial choice for surveillance or prophylactic mastectomy. The study provides presumptive evidence that educational-support group participants decide to undergo prophylactic mastectomy earlier than non-attendees.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19967456     DOI: 10.1007/s10689-009-9311-3

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  27 in total

1.  Intention to undergo prophylactic bilateral mastectomy in women at increased risk of developing hereditary breast cancer.

Authors:  B Meiser; P Butow; M Friedlander; V Schnieden; M Gattas; J Kirk; G Suthers; E Haan; K Tucker
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

2.  Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing.

Authors:  Jeffrey R Botkin; Ken R Smith; Robert T Croyle; Bonnie J Baty; Jean E Wylie; Debra Dutson; Anna Chan; Heidi A Hamann; Caryn Lerman; Jamie McDonald; Vickie Venne; John H Ward; Elaine Lyon
Journal:  Am J Med Genet A       Date:  2003-04-30       Impact factor: 2.802

3.  Psychosocial care in family cancer clinics in The Netherlands: a brief report.

Authors:  E M Bleiker; F J Grosfeld; D E Hahn; C Honing
Journal:  Patient Educ Couns       Date:  2001-05

4.  Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing.

Authors:  C Lerman; C Hughes; R T Croyle; D Main; C Durham; C Snyder; A Bonney; J F Lynch; S A Narod; H T Lynch
Journal:  Prev Med       Date:  2000-07       Impact factor: 4.018

5.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

Review 6.  Prophylactic mastectomy for the prevention of breast cancer.

Authors:  L Lostumbo; N Carbine; J Wallace; J Ezzo
Journal:  Cochrane Database Syst Rev       Date:  2004-10-18

7.  Cancer Incidence in BRCA1 mutation carriers.

Authors:  Deborah Thompson; Douglas F Easton
Journal:  J Natl Cancer Inst       Date:  2002-09-18       Impact factor: 13.506

8.  Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.

Authors:  Marcia S Brose; Timothy R Rebbeck; Kathleen A Calzone; Jill E Stopfer; Katherine L Nathanson; Barbara L Weber
Journal:  J Natl Cancer Inst       Date:  2002-09-18       Impact factor: 13.506

Review 9.  Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review.

Authors:  M J Bermejo-Pérez; S Márquez-Calderón; A Llanos-Méndez
Journal:  Int J Cancer       Date:  2007-07-15       Impact factor: 7.396

10.  Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study.

Authors:  Iris van Oostrom; Hanne Meijers-Heijboer; Litanja N Lodder; Hugo J Duivenvoorden; Arthur R van Gool; Caroline Seynaeve; Conny A van der Meer; Jan G M Klijn; Bert N van Geel; Curt W Burger; Juriy W Wladimiroff; Aad Tibben
Journal:  J Clin Oncol       Date:  2003-10-15       Impact factor: 44.544

View more
  8 in total

1.  Perspectives of Women Considering Bilateral Prophylactic Mastectomy and their Peers towards a Telephone-Based Peer Support Intervention.

Authors:  D St-Pierre; K Bouchard; L Gauthier; J Chiquette; Michel Dorval
Journal:  J Genet Couns       Date:  2017-09-15       Impact factor: 2.537

2.  Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome.

Authors:  Pascale This; Anne de la Rochefordière; Alexia Savignoni; Marie Christine Falcou; Anne Tardivon; Fabienne Thibault; Séverine Alran; Virgine Fourchotte; Alfred Fitoussi; Benoit Couturaud; Sylvie Dolbeault; Remy J Salmon; Brigitte Sigal-Zafrani; Bernard Asselain; Dominique Stoppa-Lyonnet
Journal:  Fam Cancer       Date:  2012-09       Impact factor: 2.375

Review 3.  Outcomes of support groups for carriers of BRCA 1/2 pathogenic variants and their relatives: a systematic review.

Authors:  Benedetta Bertonazzi; Daniela Turchetti; Lea Godino
Journal:  Eur J Hum Genet       Date:  2022-01-26       Impact factor: 4.246

4.  Experiencing the cancer of a loved one influences decision-making for breast cancer prevention.

Authors:  Tasleem J Padamsee; Anna Muraveva; Lisa D Yee; Celia E Wills; Electra D Paskett
Journal:  J Health Psychol       Date:  2017-12-15

5.  Seeking balance: decision support needs of women without cancer and a deleterious BRCA1 or BRCA2 mutation.

Authors:  Meghan L Underhill; Cheryl B Crotser
Journal:  J Genet Couns       Date:  2013-11-22       Impact factor: 2.537

6.  Group medical visits in the follow-up of women with a BRCA mutation: design of a randomized controlled trial.

Authors:  Annemiek Visser; Judith B Prins; Nicoline Hoogerbrugge; Hanneke W M van Laarhoven
Journal:  BMC Womens Health       Date:  2011-08-24       Impact factor: 2.809

7.  Anxiety and depression symptoms among women attending group-based patient education courses for hereditary breast and ovarian cancer.

Authors:  Wenche Listøl; Hildegunn Høberg-Vetti; Geir Egil Eide; Cathrine Bjorvatn
Journal:  Hered Cancer Clin Pract       Date:  2017-01-11       Impact factor: 2.857

Review 8.  Decision making for breast cancer prevention among women at elevated risk.

Authors:  Tasleem J Padamsee; Celia E Wills; Lisa D Yee; Electra D Paskett
Journal:  Breast Cancer Res       Date:  2017-03-24       Impact factor: 6.466

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.